Patents Assigned to Esperion Therapeutics, Inc.
-
Patent number: 6617134Abstract: Substantially pure dimers of Apolipoprotein AI-Milano (APO-AI-M/APO AI-M) were isolated from plasma and characterized. Apolipoprotein AI-M dimer can also be produced in a recombinant Escherichia coli system. Pharmaceutical compositions comprising the ApoAI-AI-M/ApoAI-M are described. Patients with atherosclerosis or cardiovascular diseases can be treated with the dimer. Medicaments containing the dimer can also be used to prevent thrombosis in different clinical circumstances, both at the arterial and at the venous level. The dimer can also act as a prodrug for the monomer.Type: GrantFiled: March 1, 1999Date of Patent: September 9, 2003Assignee: Esperion Therapeutics, Inc.Inventors: Cesare Sirtori, Guido Franceschini, Lars Abrahmsén, Erik Holmgren, Mats Lake, Björn Nilsson, Joanna Chmielewska, Peter Lind
-
Publication number: 20030149094Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: ApplicationFiled: November 26, 2002Publication date: August 7, 2003Applicant: Esperion Therapeutics, Inc.Inventor: Jean-Louis Henri Dasseux
-
Publication number: 20030125559Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: ApplicationFiled: April 26, 2002Publication date: July 3, 2003Applicant: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
-
Publication number: 20030109442Abstract: Apolipoprotein A-I (ApoA-I), preferably a variant form such as Apolipoprotein A-I Milano (ApoA-IM), alone or more preferably in combination with a lipid carrier such as phospholipids or other drug, can be administered locally before or during bypass surgery on diseased coronary, peripheral, and cerebral arteries, surgery to implant grafts or transplanted organs, or angioplasty, or to stabilize unstable plaques. In an alternative embodiment, the apolipoprotein is not provided directly, but the gene encoding the apolipoprotein is provided. The gene is introduced into the blood vessel in a manner similar to that used for the protein, where the protein is then expressed. The technique can also be used for delivery of genes for treatment or prevention or restenosis or other cardiovascular diseases.Type: ApplicationFiled: September 27, 2002Publication date: June 12, 2003Applicants: Esperion Therapeutics, Inc., Cedars-Sinai Medical CenterInventors: Charles L. Bisgaier, Prediman Krishan Shah, Sanjay Kaul
-
Patent number: 6559284Abstract: The present invention relates to a composition for use in purification of apolipoprotein A (ApoA) or apolipoprotein E (ApoE), said composition comprising a first and a second polymeric material, wherein the first and second polymeric material are immiscible in the primary aqueous solution, and wherein the second polymeric material is amphiphilic and water soluble. The invention further relates to a process for purifying ApoA or ApoE, or variants or mixtures thereof, by first mixing ApoA or ApoE, the composition containing a first and second polymeric material and water. The resulting primary aqueous solution is maintained for a period of time sufficient for essentially separating the phases formed, and removing the phase containing the second polymeric material and the main portion of ApoA or ApoE. Subsequently, the second polymeric material is separated from ApoA or ApoE.Type: GrantFiled: September 5, 1997Date of Patent: May 6, 2003Assignee: Esperion Therapeutics, Inc.Inventors: Hans Ageland, Lena Nyström, Josefine Persson, Folke Tjerneld
-
Publication number: 20030065195Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: ApplicationFiled: July 26, 2002Publication date: April 3, 2003Applicant: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
-
Patent number: 6506799Abstract: The present invention relates to methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension comprising administering a composition comprising an ether compound.Type: GrantFiled: March 31, 2000Date of Patent: January 14, 2003Assignee: Esperion Therapeutics, Inc.Inventor: Jean-Louis Henri Dasseux
-
Patent number: 6506879Abstract: A substantially endotoxin-free ApoA or ApoE is produced by recombinant DNA technique, suitably in E. coli. Medicaments and methods for treatment of atherosclerosis or cardiovascular diseases employ ApoA or ApoE purified by a process comprising contacting a first aqueous solution comprising ApoA or ApoE and endotoxins with a matrix comprising an immobilized compound with an end group comprising two or three nitrogen atoms bonded to a carbon atom for attaching the endotoxins to the matrix, and subsequently treating the matrix comprising the immobilized compound with a second aqueous solution comprising a surfactant for releasing the ApoA or ApoE while the endotoxins remain attached to the matrix.Type: GrantFiled: November 22, 1999Date of Patent: January 14, 2003Assignee: Esperion Therapeutics, Inc.Inventors: Hans Ageland, Lena Romander
-
Publication number: 20030008827Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.Type: ApplicationFiled: May 25, 2001Publication date: January 9, 2003Applicant: Esperion Therapeutics, Inc.Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Buttner, Isabelle Cornut, Gunther Metz
-
Patent number: 6459003Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: GrantFiled: March 31, 2000Date of Patent: October 1, 2002Assignee: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
-
Patent number: 6423830Abstract: The present invention relates to a process for purifying apolipoprotein A (ApoA) or apolipoprotein E (ApoE) from human plasma, by obtaining a fraction of human plasma containing said ApoA or ApoE, prepurifying said fraction in at least one step, binding said ApoA or ApoE to an anion-exchange chromatography gel, and thereafter eluting said ApoA or ApoE from said anion-exchange chromatography gel. The thus produced ApoA or ApoE can be used for the manufacture of a medicament in the treatment of atherosclerosis and cardiovascular diseases, or peripheral atherosclerosis and sepsis as well as in a method for treatment of atherosclerosis and cardiovascular diseases, or peripheral atherosclerosis and sepsis when administered in a therapeutically effective amount.Type: GrantFiled: July 17, 2000Date of Patent: July 23, 2002Assignee: Esperion Therapeutics, Inc.Inventors: Stefan Winge, Sara Wiklund
-
Patent number: 6410802Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: GrantFiled: March 31, 2000Date of Patent: June 25, 2002Assignee: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
-
Patent number: 6376464Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.Type: GrantFiled: December 1, 1999Date of Patent: April 23, 2002Assignee: Esperion Therapeutics, Inc.Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
-
Patent number: 6329341Abstract: The present invention provides peptides and petptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.Type: GrantFiled: December 1, 1999Date of Patent: December 11, 2001Assignee: Esperion Therapeutics, Inc.Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
-
Patent number: 6287590Abstract: The invention relates to the formation of peptide/lipid vesicles and complexes through the co-lyophilization of peptides, preferably that are able to adopt an amphipathic alphahelical conformation, and one or more lipids. A single solution which solubilizes both the peptides and lipids or two separate solutions may be lyophilized.Type: GrantFiled: October 2, 1997Date of Patent: September 11, 2001Assignee: Esperion Therapeutics, Inc.Inventor: Jean-Louis Dasseux
-
Patent number: 6090921Abstract: The present invention relates to a process for purifying apolipoprotein A (ApoA) or apolipoprotein E (ApoE) from human plasma, by obtaining a fraction of human plasma containing said ApoA or ApoE, prepurifying said fraction in at least one step, binding said ApoA or ApoE to an anion-exchange chromatography gel, and thereafter eluting said ApoA or ApoE from said anion-exchange chromatography gel. The thus produced ApoA or ApoE can be used for the manufacture of a medicament in the treatment of atherosclerosis and cardiovascular diseases, or peripheral atherosclerosis and sepsis as well as in a method for treatment of atherosderosis and cardiovascular diseases, or peripheral atherosclerosis and sepsis when administered in a therapeutically effective amount.Type: GrantFiled: August 15, 1997Date of Patent: July 18, 2000Assignee: Esperion Therapeutics, Inc.Inventors: Stefan Winge, Sara Wiklund
-
Patent number: 5990081Abstract: A substantially endotoxin-free ApoA or ApoE is produced by recombinant DNA technique, suitably in E. coli. Medicaments and methods for treatment of atherosclerosis or cardiovascular diseases employ ApoA or ApoE purified by a process comprising contacting a first aqueous solution comprising ApoA or ApoE and endotoxins with a matrix comprising an immobilized compound with an end group comprising two or three nitrogen atoms bonded to a carbon atom for attaching the endotoxins to the matrix, and subsequently treating the matrix comprising the immobilized compound with a second aqueous solution comprising a surfactant for releasing the ApoA or ApoE while the endotoxins remain attached to the matrix.Type: GrantFiled: August 5, 1998Date of Patent: November 23, 1999Assignee: Esperion Therapeutics, Inc.Inventors: Hans Ageland, Lena Romander